Welcome to our dedicated page for Marpai SEC filings (Ticker: MRAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Marpai, Inc. (MRAI) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Marpai’s filings describe its business as a technology platform company operating subsidiaries that provide Third-Party Administration (TPA), Pharmacy Benefit Management (PBM) and value-oriented health plan services to employers that directly pay for employee health benefits. Its Class A common stock is listed on the OTCQX Market under the symbol MRAI.
Through periodic and current reports, Marpai presents financial statements, details of its operating performance and information about its capital structure. For example, Form 8-K filings included in this record describe private placements of Class A common stock and warrants under Securities Purchase Agreements, with proceeds intended for working capital and general corporate purposes. Other 8-K filings reference amendments to the company’s certificate of incorporation, such as the authorization of blank-check preferred stock, and the release of selected financial information for specific reporting periods.
Annual proxy materials, such as the definitive proxy statement (DEF 14A), outline governance matters, including the election of directors, ratification of the independent registered public accounting firm and proposals to amend the certificate of incorporation. These documents also confirm key facts such as Marpai’s Delaware incorporation, its Tampa, Florida office location and the voting rights associated with its Class A common stock.
On this page, users can review Marpai’s Forms 10-K and 10-Q (when available), current reports on Form 8-K, proxy statements and other filings. Stock Titan’s tools can surface summaries and key points from longer documents, helping readers understand topics such as equity issuances, changes to the capital structure, governance proposals and how Marpai presents its TPA and PBM operations in official filings.
Marpai, Inc. director Eitan Yaron received 75,000 restricted stock units (RSUs) that vested on a nine-month schedule and now beneficially owns 864,073 shares following the reported transactions. The RSUs vested in three tranches of 25,000 shares at three, six and nine months after grant, and the filing amends a prior Form 4 to correct the previously misstated post-transaction ownership total.
Marpai, Inc. reported that on September 10, 2025, it entered into a Securities Purchase Agreement with three investors for a private sale of its Class A common stock. The company agreed to issue and sell 1,038,519 shares of common stock at $1.0592 per share.
The investor group includes HillCour Investment Fund, LLC, an entity controlled by Chief Executive Officer Damien Lamendola, which purchased 896,903 shares. The transaction was structured as a private placement relying on exemptions from registration under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D. The shares have not been registered and may only be resold in the United States under a registration statement or a valid exemption.
Marpai, Inc. (MRAI) director Eitan Yaron acquired 75,000 restricted stock units (RSUs) on 08/19/2025 under a grant that vests in three equal tranches over nine months. The filing reports these RSUs were recorded at $0 price and, after the grant, Mr. Yaron beneficially owns 1,542,527 shares. The Form 4 indicates the reporting person is a director and the transaction was a non-derivative acquisition of Class A common stock RSUs.
Marpai, Inc. director Shiv Sagiv reported the vesting and acquisition of 75,000 restricted stock units (RSUs) on 08/19/2025, increasing his beneficial ownership to 135,000 shares of Class A common stock. The filing indicates the RSUs were granted under a plan with a nine-month vesting schedule: 25,000 RSUs vested at three months, 25,000 at six months, and 25,000 at nine months.
The Form 4 was signed on 09/15/2025 and notes the transaction was made pursuant to a plan intended to meet the Rule 10b5-1 affirmative defense. Sagiv is identified as a director. No options or derivative transactions are reported in this filing.
Jennifer Calabrese, a director of Marpai, Inc. (MRAI), reported the vesting and acquisition of 75,000 restricted stock units (RSUs) on 08/19/2025. The Form 4 shows the 75,000 RSUs were acquired with a reported price of $0.00 and resulted in 125,000 shares of Class A common stock beneficially owned following the transaction. The filing indicates the transaction was made pursuant to a written plan intended to satisfy Rule 10b5-1(c) affirmative defense conditions and that the RSUs vest over nine months in three equal tranches of 25,000 RSUs at three, six and nine months from the grant date.
The Form 4 was filed as an individual report and signed by Ms. Calabrese on 09/15/2025.